Vonoprazan: A Review in Helicobacter pylori Infection

Abstract

Treatment for the eradication of Helicobacter pylori infection, a leading cause of peptic ulcer disease and an important risk factor for gastric cancer and mucosa-associated lymphoid tissue lymphoma, is indicated whenever infection is identified. However, treatment success rates with current guideline-recommended proton-pump inhibitor (PPI)-based regimens remain suboptimal, with one potential factor associated with treatment failure being inadequate acid suppression. Vonoprazan (Voquezna ® ) is a first-in-class potassium-competitive acid blocker with the potential to provide potent and sustained acid suppression. Following clinical trials conducted mainly in Asia (supported by post-marketing experience from Asia) and the phase III PHALCON-HP trial conducted in the USA and Europe, vonoprazan is now approved in the USA for use in combination with amoxicillin (dual therapy) or amoxicillin and clarithromycin (triple therapy) for the treatment of H. pylori infection in adults. The vonoprazan-based dual and triple therapy regimens were generally well tolerated in PHALCON-HP. In addition, vonoprazan has advantages including a rapid onset of action and no food effect, making vonoprazan-based dual and triple therapy regimens valuable alternatives to standard PPI-based triple therapy in the treatment of H. pylori infection. Supplementary Information The online version contains supplementary material available at 10.1007/s40265-023-01991-5.

Helicobacter pylori Infection in Patients with Gastric Cancer: A 2024 Update

“…[52] In PHALCON-HP, the dual-and triple-therapy regimens based on vonoprazan were typically well tolerated. [53] Pharmacological combinations such as vonoprazan and amoxicillin have synergistic results.…”

“…Vonoprazan, also known as Voquezna ® , is a powerful and long-lasting acid blocker that is a first-class potassium-competitive drug. Adults with H. pylori infection can now receive approval in the USA to use amoxicillin-vonoprazan dual therapy [ 53 ]. Novel approaches were devised to efficiently resolve and precisely quantify the overlapping spectra of amoxicillin and vonoprazan.…”